The anti-PD-1 immune checkpoint inhibitor (ICI) pembrolizumab blocks the T-cell-inhibitory programmed cell death protein 1 (PD-1) pathway and has gained tumor agnostic approval for treatment of high mutational burden tumors and tumors expressing programmed death ligand 1 (PD-L1) (1, 2). This evidence concerns the gene CD274 and neoplasm.